BioGenes successfully DIN EN ISO 9001:2000 certified
Berlin. The Berlin-based Biotech-Company BioGenes, one of Europe's leading suppliers in the field of immunological services and antibody development, has successfully been DIN EN ISO 9001:2000 certified. Following an audit procedure lasting several days the external certifying body TÜV Rheinland Group Berlin/Brandenburg has certified BioGenes to be in full compliance with all demands and quality standards of that international standard.
The EN ISO 9001:2000 serves manufacturers and service providers as an international standard for the implementation of a quality management system and aims for the continual improvement of processes, a constantly high quality standard as well as the resulting higher customer satisfaction. Especially on the international level customers as well as business partners and suppliers increasingly expect such quality certificates.
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
DNA damage response protein
Chempolis to supply three biorefineries to China

Genes against drought

Fierce competition between the human immune system and bacterial pathogens - New insights into the recent development of the human immune system

Merck off to a Good Start in Fiscal 2024 - The positive development of Healthcare and Electronics largely compensated for the decline in Life Science
'Tearless' onions could help in the fight against cardiovascular disease
Charles_McIlvaine
Agendia expands its business activities in Germany
Drägerwerk: Turnaround program already saved around EUR 45 million in 2009
Bacteria on marine sponges can develop capacity to move and inhibit biofilm formation

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology - Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
